Can lung cancer patients skip brain radiation? new trial investigates

NCT ID NCT05987644

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 22 times

Summary

This study looks at whether people with lung cancer that has spread to the brain can safely delay radiation therapy if they take the targeted drug alectinib. It involves 56 adults with specific genetic changes. The goal is to see if alectinib alone controls brain tumors as well as alectinib plus radiation, while reducing side effects like cognitive decline.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ohio State University Comprehensive Cancer Center

    RECRUITING

    Columbus, Ohio, 43210, United States

    Contact Email: •••••@•••••

    Contact

  • Stanford University

    RECRUITING

    Stanford, California, 94305, United States

    Contact Email: •••••@•••••

    Contact

  • University of Colorado Cancer Center

    RECRUITING

    Aurora, Colorado, 80045, United States

    Contact

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.